Background: Fatigue is the most commonly reported symptom in patients with persistent complaints following COVID-19 (ie, long COVID). Longitudinal studies examining the intensity of fatigue and differentiating between physical and mental fatigue are lacking.
Objective: The objectives of this study were to (1) assess the severity of fatigue over time in members of online long COVID peer support groups, and (2) assess whether members of these groups experienced mental fatigue, physical fatigue, or both.
Methods: A 2-wave web-based follow-up study was conducted in members of online long COVID peer support groups with a confirmed diagnosis approximately 3 and 6 months after the onset of infectious symptoms. Demographics, COVID-19 diagnosis, received health care (from medical professionals or allied health care professionals), fatigue (Checklist Individual Strength–subscale subjective fatigue [CIS-Fatigue]; 8-56 points), and physical and mental fatigue (self-constructed questions; 3-21 points) were assessed. Higher scores indicated more severe fatigue. A CIS-Fatigue score ≥36 points was used to qualify patients as having severe fatigue.
Results: A total of 239 patients with polymerase chain reaction/computed tomography–confirmed COVID-19 completed the survey 10 weeks (SD 2) and 23 weeks (SD 2) after onset of infectious symptoms, respectively (T1 and T2). Of these 239 patients, 198 (82.8%) were women; 142 (59.4%) had no self-reported pre-existing comorbidities; 208 (87%) self-reported being in good health before contracting COVID-19; and 62 (25.9%) were hospitalized during acute infection. The median age was 50 years (IQR 39-56). The vast majority of patients had severe fatigue at T1 and T2 (n=204, 85.4%, and n=188, 78.7%, respectively). No significant differences were found in the prevalence of normal, mild, and severe fatigue between T1 and T2 (P=.12). The median CIS-Fatigue score was 48 points (IQR 42-53) at T1, and it decreased from T1 to T2 (median change: –2 points, IQR –7 to 3; P<.001). At T1, a median physical fatigue score of 19 points (IQR 16-20) and a median mental fatigue score of 15 points (IQR 10-17) were reported; these scores were lower at T2 for physical but not for mental fatigue (median change for physical fatigue –1 point, IQR –3 to 0, P<.001; median change for mental fatigue 0 points, IQR –3 to 3, P=.52). At the time of completing the follow-up survey, 194/239 (81.2%) and 164/239 (68.6%) of all patients had received care from at least one medical professional and one allied health care professional, respectively.
Conclusions: Fatigue in members of online long COVID support groups with a confirmed COVID-19 diagnosis decreases from 10 to 23 weeks after onset of symptoms. Despite this, severe fatigue remains highly prevalent. Both physical and mental fatigue are present. It remains unclear whether and to what extent fatigue will resolve spontaneously in the longer term.
Trial Registration: Netherlands Trial Register NTR8705; https://www.trialregister.nl/trial/8705.
As the current COVID-19 pandemic continues to evolve, its impact becomes apparent. Clinical studies of hospitalized, laboratory-confirmed patients have shown that the acute phase of COVID-19 is characterized by a large array of respiratory and non-respiratory symptoms . Over time, it has become clear that not all previously hospitalized patients fully recover from these symptoms in the months after the infection [ , ]. In addition, nonhospitalized patients can present persistent complaints months after the onset of infection-related symptoms [ ]. These long-lasting symptoms after COVID-19 are referred to as long COVID [ ], “a condition whereby affected individuals do not recover for several weeks or months following the onset of symptoms suggestive of COVID-19” [ ], and they have a major impact on patients’ quality of life (QoL) [ , ], care dependency [ ], work participation [ , ], day-to-day activities, and physical functioning [ - ].
Fatigue, defined as “a subjective, unpleasant symptom which incorporates total body feelings ranging from tiredness to exhaustion creating an unrelenting overall condition which interferes with individuals’ ability to function to their normal capacity” , is the most commonly reported symptom in patients with long COVID [ - , ]. Similarly, other infections, such as severe acute respiratory syndrome (SARS) [ , ], Middle East respiratory syndrome (MERS) [ ], and Q fever [ ] have previously been linked to long-term fatigue, often referred to as postviral fatigue syndrome. Existing literature suggests that fatigue has several clinical presentations. A common distinction is made between physical fatigue (ie, difficulty performing physical activities) and mental fatigue (ie, difficulties concentrating and performing cognitive tasks) [ ].
To date, longitudinal studies that examine fatigue intensity in patients with long COVID are lacking. Moreover, it is not known whether patients experience mostly mental or physical fatigue during and after the infection. Therefore, the objectives of this study were to (1) assess the severity of fatigue over time in members of online long COVID peer support groups; and (2) assess whether members of online long COVID peer support groups experience mental fatigue, physical fatigue, or both. We hypothesized that fatigue would be common and persistent and that both physical and mental fatigue would be present in patients with long COVID.
Study Design and Participants
This study is a prospective web-based survey of members of two Facebook peer support groups for patients with long COVID in the Netherlands (approximately 11,000 members; ) and Flanders (Belgium, approximately 1200 members; [ ]), and a panel of approximately 1200 people who registered at a website of the Netherlands Lung Foundation (coronaplein [ ]), an online platform providing additional information, advice, and peer support. Note that these totals represent the number of members of each group at the period of data collection. Between June 4 and June 11, 2020 (the time point of completing the first survey [T1]), members were invited to complete a web-based survey. Participants who completed the first survey [ , , ] and who agreed to be contacted for a follow-up study received a second survey between August 31 and September 8, 2020 (ie, approximately three months after the first survey; the time point of completing the second survey [T2]). Ethical approval for this study was waived by the medical ethics committee of Maastricht University because the Medical Research Involving Human Subjects Act (WMO) does not apply to this study (METC2020-1978 and METC2020-2254). The medical ethics committee of Hasselt University formally judged and approved the study (MEC2020/041). Digital informed consent was obtained twice from all respondents (at the start of each survey). Exclusion criteria were intensive care unit (ICU) admission during the acute phase of infection, an onset of symptoms before January 1, 2020, being in the acute phase of COVID-19 when answering the first survey (ie, onset of infectious symptoms less than 3 weeks before filling out the first survey [ ]), or an incomplete survey. Cross-sectional and follow-up data from this study on persistent symptoms, QoL, care dependency, construct-validity of the post–COVID-19 functional status scale, and information and care needs of members of online long COVID peer support groups have been published before [ , , , , , ]. This 2-wave web-based follow-up study was registered at the Netherlands Trial Registry (NTR8705). The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) checklist was used to guide reporting [ ]. Of note: the current study focusses on patients with a confirmed COVID-19 diagnosis (ie, test-diagnosed cases). The results for the patients without a confirmed COVID-19 diagnosis are presented in .
Assessment via Web-Based Surveys
The survey was developed in close collaboration with scientists, methodologists, health care professionals and COVID-19 patients from the long COVID peer support groups (the Netherlands and Flanders). It was digitalized by ASolutions  and was made available via their online platform. The survey consisted of general questions regarding demographics, clinical characteristics, and standardized questionnaires, including a fatigue questionnaire.
Demographic and Clinical Characteristics
Respondents received questions regarding demographical aspects such as gender, age, weight, height, educational level (low/medium/high; classification according to the International Standard Classification of Education 2011 ), and married/living with a partner (yes/no). In addition, the following clinical characteristics were assessed via self-report: pre-existing comorbidities (see ), health status (good/moderate/poor) during the infection and at the moment of completing the surveys, date of symptom onset, symptoms during acute phase of COVID-19 and at the moment of completing the surveys (see ), COVID-19–related hospitalization, and COVID-19 diagnosis (based on reverse transcription polymerase chain reaction (PCR) test or computed tomography (CT) scan of the thorax/symptom-based medical diagnosis by a physician/no formal test or diagnosis). Based upon the latter, patients were classified as either “test-diagnosed” COVID-19 (PCR or CT) or “presumed” COVID-19 (physician-diagnosed or no formal diagnosis/testing).
Received Health Care
Information regarding received health care (yes/no) by a medical professional (eg, medical specialist; general practitioner [GP]; nurse) or an allied health care professional (AHP; eg, physiotherapist [PT]; psychologist; occupational therapist [OT]; dietician; speech and language therapist) was recorded.
Standardized Fatigue Questionnaire
Fatigue, the primary outcome measure, was measured using a subscale of the Checklist Individual Strength (CIS). The Checklist Individual Strength–subscale subjective fatigue (CIS-Fatigue) is a standardized questionnaire [, ] with high internal consistency and test-retest reliability; good discriminant, concurrent and criterion validity; and ability to detect change in subjective fatigue [ - ]. The questionnaire consists of 8 items scored on a 7-point Likert scale. Scores range from 8 to 56 points, and a higher score indicates more clinical symptoms of general fatigue (see for the CIS-Fatigue questionnaire) [ , ]. Based upon validated cutoff values, individuals can be classified as having normal (≤26 points), mild (27-35 points), and severe (≥36 points) fatigue [ - ].
Self-constructed Physical and Mental Fatigue Questions
A total of 3 self-constructed questions (all part of the CIS-Fatigue subscale) were used to evaluate physical fatigue (“Physically I feel exhausted,” “Physically I feel I am in a bad condition,” and “Physically I feel in a good shape”). In addition, to differentiate between physical and mental fatigue, 3 questions were constructed in which the word “physically” was replaced by the word “mentally” (“Mentally I feel exhausted,” “Mentally I feel I am in a bad condition,” and “Mentally I feel in a good shape,” respectively) to estimate mental fatigue. The physical and mental fatigue questions were scored on a 7-point Likert scale, with scores ranging from 3 to 21 points. A higher score indicates worse physical and mental fatigue, respectively. These self-constructed physical and mental fatigue questions and explanations of the scoring are reported in.
Data are presented as means and standard deviations, medians, and interquartile ranges or as frequencies and proportions, where appropriate. Differences over time were analyzed by a paired t-test (or Wilcoxon signed-rank test) in continuous data and a McNemar test (or McNemar-Bowker test) in categorical data. If significant, a post hoc comparison of the McNemar-Bowker test was performed, and significant Bonferroni-adjusted P values were generated as corrections for multiple comparison. Statistical analyses were conducted using SPSS 25.0 (IBM Corporation). Figures were generated via GraphPad Prism 8.3.5 (GraphPad Software) and SankeyMATIC . The level of significance was set at .01 for all statistical tests (two-tailed).
In total, 2159 members of online long COVID peer support groups filled out the first survey, of which 220 were excluded for being in the acute phase of COVID-19 (n=14), ICU admission during the acute phase of COVID-19 (n=15), onset of symptoms before January 1, 2020 (n=8), and an incomplete first survey (n=183). From the 1939 patients who were included, 1556 consented to be approached for follow-up research, of which 1005 (64.6%) completed the second survey. Patients who did not respond to the second survey were younger and more often had a presumed COVID-19 diagnosis. Further details can be found in a previously published paper . The 1005 patients completed the surveys on average 11.3 weeks (SD 2.2) and 23.5 weeks (SD 2.2) after onset of symptoms (T1 and T2, respectively). Overall, 239 test-diagnosed (hospitalized, n=62, and nonhospitalized, n=177) and 766 presumed (physician-diagnosed, n=454, and patients with no formal diagnosis/testing, n=312) patients with COVID-19 participated in this 2-wave web-based survey (see for the flowchart).
Demographical and Clinical Characteristics
Patients with confirmed COVID-19 were mostly middle-aged women (median age 50.0 years, IQR 39.0-56.0; 198/239 women, 82.8%) with a BMI indicating slight overweight (median BMI 26.0 kg/m2, IQR 23.4-30.5), and they completed the first (T1) and second (T2) survey on average 10.4 weeks (SD 2.4) and 22.6 weeks (SD 2.4) after onset of symptoms. Approximately 1 out of 4 patients (62/239, 25.9%) was hospitalized during the acute phase of COVID-19. The majority of respondents had no self-reported comorbidities (142/239, 59.4%) and good self-reported health status before the infection (208/239, 87%). Moreover, at T1 and T2, a minority of respondents self-reported good health (22/239, 9.2%, and 40/239, 16.7%, respectively ). Furthermore, patients retrospectively reported a median of 15 symptoms (IQR 11-18) during the acute phase of COVID-19, and 6 symptoms (IQR 4-9) and 6 symptoms (IQR 3-8) at T1 and T2, respectively. All details regarding patient characteristics can be found in .
|Women, n (%)||198 (82.8)|
|Age (years), median (IQR)||50.0 (39.0-56.0)|
|BMI (kg/m2), median (IQR)||26.0 (23.4-30.5)|
|Time between onset of symptoms and T1a survey (weeks), mean (SD)||10.4 (2.4)|
|Time between onset of symptoms and T2b survey (weeks), mean (SD)||22.6 (2.4)|
|Married/living with partner, n (%)||173 (72.4)|
|Educational level, n (%)|
|Pre-existing comorbidities, n (%)|
|Health status before infection, n (%)|
|Health status at T1, n (%)|
|Number of symptoms, median (IQR)|
|During acute infection||15 (11-18)|
|At T1||6 (4-9)|
|At T2||6 (3-8)|
|Hospitalized during acute infection, n (%)||62 (25.9)|
aT1: time of completing the first survey.
bT2: time of completing the second survey.
Received Health Care
During the first 10 weeks after the onset of symptoms, 2 out of 3 patients (157/239, 65.7%) received or sought care from at least one medical professional (GP: 139/239, 58.2%; medical specialist: 73/239, 30.5%; nurse: 18/239, 7.5%), whereas 1 out of 3 (90/239, 37.7%) received or sought care from at least one allied health care professional (PT: 76/239, 31.8%; psychologist: 27/239, 11.3%; OT: 7/239, 2.9%, dietician: 25/239, 10.5%; and speech and language therapist: 6/239, 2.5%). The cumulative proportion of patients who received care from a medical professional and allied health care professional at T2 respectively increased significantly to 81.2% (194/239; GP: 170/239, 71.1%; medical specialist: 131/239, 54.8%; nurse: 32/239, 13.4%; all P<.001) and 68.6% (164/239; PT: 157/239, 65.7%; psychologist: 55/239, 23%; OT: 27/239, 11.3%; dietician, 51/239, 21.3%; speech and language therapist, 21/239, 8.8%; all P<.001). Furthermore, the cumulative proportion of patients who participated in an interdisciplinary rehabilitation program (in- or outpatient) increased significantly from T1 to T2 (10/239, 4.2%, to 32/239, 13.4%, respectively; P<.001). Details regarding received health care can be found in.
|General fatigue (points on CIS-Fatiguec scale), median (IQR)||48 (42-53)||46 (37-50)||<.001|
|Severe fatigue, n (%)||204 (85.4)||188 (78.7)||.03|
|Mental fatigue (points on self-constructed questions), median (IQR)||15 (10-17)||14 (10-17)||.52|
|Physical fatigue (points on self-constructed questions), median (IQR)||19 (16-20)||18 (14-19)||<.001|
|Received health care from a medical professional, n (%)|
|Received care from ≥1 medical professionals||157 (65.7)||194 (81.2)||<.001|
|General practitioner||139 (58.2)||170 (71.1)||<.001|
|Medical specialist||73 (30.5)||131 (54.8)||<.001|
|Nurse||18 (7.5)||32 (13.4)||<.001|
|Received health care from an allied health care provider, n (%)|
|Received care from ≥1 allied health care providers||90 (37.7)||164 (68.6)||<.001|
|Physiotherapist||76 (31.8)||157 (65.7)||<.001|
|Psychologist||27 (11.3)||55 (23)||<.001|
|Occupational therapist||7 (2.9)||27 (11.3)||<.001|
|Dietician||25 (10.5)||51 (21.3)||<.001|
|Speech and language therapist||6 (2.5)||21 (8.8)||<.001|
|Rehabilitation (in- or outpatient), n (%)||10 (4.2)||32 (13.4)||<.001|
aT1: time of completing the first survey.
bT2: time of completing the second survey.
cCIS-Fatigue: Checklist Individual Strength–subscale subjective fatigue.
Standardized Fatigue Questionnaire
Patients with confirmed COVID-19 reported a median CIS-Fatigue score of 48 points (IQR 42-53) at T1. The majority (204/239, 85.4%) reported severe fatigue at approximately 3 months after the onset of COVID-19 symptoms. The median CIS-Fatigue score improved significantly between T1 and T2 (median change –2 points, IQR –7 to 3; P<.001) (), whereas no significant differences were found in the proportions of normal, mild, or severe fatigue (P=.12). An overview of the proportions of patients with normal, mild, and severe fatigue at T1 and T2, the proportional flow, and the direction of change can be found in . In addition, shows the proportion, flow, and direction of the change of fatigue stratified for the type of diagnosis (ie, hospitalized and nonhospitalized test-diagnosed patients, physician-diagnosed patients, and patients without a formal diagnosis/test).
Self-constructed Physical and Mental Fatigue Questions
Patients with confirmed COVID-19 reported median physical and mental fatigue scores of 19 points (IQR 16-20) and 15 points (IQR 10-17) at T1. Between T1 and T2, a significant decrease was found in physical fatigue score (median change –1 point, IQR –3 to 0; P<.001), but not in mental fatigue score (median change 0 points, IQR –3 to 3; P=.52) (). shows the distributions of patients across the spectrum of physical and mental fatigue at T1 and T2.
To the best of our knowledge, this is the first study to measure fatigue over time in members from online long COVID peer support groups with confirmed COVID-19 using a validated and standardized measurement with generic cutoff values to determine normal, mild, and severe fatigue. Our study indicates that severe fatigue is highly prevalent in patients with long COVID at approximately 3 and 6 months after the infection. Furthermore, our longitudinal follow-up data suggest that fatigue does not resolve over time in all patients, even if they receive health care. In addition, patients experience both physical and mental fatigue.
Fatigue is the most prominent symptom in patients with long COVID [, ], irrespective of the severity of the initial infection [ ]. Nevertheless, most studies are cross-sectional and use a binary question (eg, fatigued/not fatigued) to assess the prevalence of fatigue [ , , ]. Therefore, little is known about the change in fatigue intensity over time [ , ]. Our study used a validated and standardized questionnaire to assess fatigue and was able to quantify fatigue intensity. Indeed, fatigue is highly prevalent in our sample. Moreover, fatigue was reported to be generally high. The median fatigue scores found in our sample are equal to or higher than those of other chronic diseases that are characterized by fatigue, such as chronic obstructive pulmonary disease [ ], asthma [ ], Q fever [ ], multiple sclerosis [ ], rheumatoid arthritis [ ], or systemic sclerosis [ ]. These findings are remarkable for such a young population with few self-reported comorbidities and good self-reported health status before the infection. Previously, other viral and nonviral infections have been linked to prolonged and debilitating fatigue [ , - ]. For example, Lam and colleagues investigated long-term complaints in SARS survivors and found that approximately one-third of SARS survivors met the modified 1994 US Centers for Disease Control and Prevention criteria for chronic fatigue syndrome more than 3 years after having SARS [ ]. Moreover, MERS survivors often experience chronic fatigue [ ]. For patients with long COVID, it remains unclear whether fatigue will resolve spontaneously in the longer term. Our follow-up data show little to no improvement in the proportion of patients with severe fatigue between 3 and 6 months, despite receiving medical and allied health care. Consequently, almost two-thirds of the patients in our sample are progressing toward chronic fatigue (ie, severe fatigue that persists longer than six months [ ]). The fact that some patients may experience debilitating chronic fatigue is worrisome and could have a major long-term impact upon these individuals as well as on the health care system and society as a whole [ , , ]. Indeed, fatigue is strongly related to health-related QoL and aspects of day-to-day life [ , , , ], and it often involves sick leave, increased health care consumption, and more hidden costs, such as informal care by friends or family members [ - ].
Fatigue is a complex and challenging symptom, as multiple factors can play a role in the initiation and maintenance of fatigue, as seen in other chronic diseases . It can present itself as mental fatigue, physical fatigue, or both [ ]. Therefore, a patient-tailored treatment based upon a holistic and comprehensive assessment of systemic, physical, psychological, and behavioral factors is proposed to alleviate the fatigue symptom burden [ ]. To date, it remains unknown which treatment strategies are effective to improve fatigue in patients with long COVID. Several treatment strategies for fatigue are proposed based upon knowledge from the fast-growing evidence regarding COVID-19 and other pathologies, such as multidisciplinary rehabilitation, energy conservation techniques, pacing, cognitive behavioral therapy, graded exercise therapy, or physical training [ , , - ]. Future research needs to provide evidence regarding underlying pathways, evaluate the effectiveness of existing treatment strategies, and identify susceptible candidates, as it is expected that not everyone will benefit from the same treatment strategy due to the multifactorial nature of fatigue. Moreover, anecdotal evidence shows that patients report having within-day and between-day variations in their daily symptoms, including fatigue [ , , ]; these cannot be captured in detail by completing a questionnaire once or twice over a longer period of time. In this, the use of an ecological momentary assessment may be valuable, as this approach involves repeated measurements of the participant’s symptoms, behavior, and context in vivo and in real time [ ]. More insights in diurnal variation in fatigue and its association with other symptoms may be useful in the development of more tailored treatment strategies for fatigue in patients with long COVID.
Methodological Considerations and Limitations
The current study has several limitations. First, the survey was only made available to members of online long COVID peer support groups. This probably caused selection bias, as it is reasonable to assume that patients with high symptom burden are more likely to become members of online long COVID peer support groups. Second, all results were collected using a web-based survey. Therefore, besides the self-reported symptoms, the patients’ height, body weight, and medical status before and during the infection were also based on self-report, which may have affected the internal validity of the current findings to some extent. Recently, the National Institute for Health and Care Excellence  proposed a case definition of long COVID whereby alternative diagnosis should be excluded when identifying patients with long COVID. Due to the nature and timing of this study (ie, early phase of the pandemic), this was not possible in the current study. Third, approximately 1 out of 3 participants who consented to be approached for follow-up research did not respond to the second wave of the survey. The authors have no information about the possible reasons for not responding to the second wave of the survey, although a between-group comparison was made to find possible differences [ ]. Fourth, the majority of our sample were women, which limits our external validity. Nevertheless, evidence is growing that women are more prone to develop long COVID [ ]. Fifth, self-constructed questions were used to quantify mental fatigue, although validated questionnaires (such as the Chalder fatigue index) to assess mental (and physical) fatigue are available [ ]. Therefore, no definite conclusions on the burden of mental fatigue in online long COVID peer support groups can be drawn based on the current study. Nevertheless, the current results indicate that COVID-19 can impact both physical and mental fatigue in the long term. Furthermore, this study was conducted in adults, although evidence regarding long COVID in children and adolescents is starting to emerge [ , ].
Severe fatigue is highly prevalent in members of online long COVID peer support groups both at approximately 3 and 6 months after onset of symptoms. As not enough time has passed since the start of the COVID-19 pandemic, it is unclear whether this fatigue will resolve spontaneously in the longer term. Future research needs to focus on the prognosis, possible causes, and treatment strategies for physical and mental fatigue in patients with long COVID.
The research team acknowledges the valuable input from the patient representatives to develop the survey, and the technical support by ASolutions’ Martijn Briejers and Oscar Wagemakers. The scientific work of YMJG is financially supported by Lung Foundation Netherlands grant 4.1.16.085, FVCM is financially supported by ZonMW (ERACoSysMed grant 90030355), and RM is financially supported by Lung Foundation Netherlands grant 188.8.131.52.
Conflicts of Interest
MAS reports grants from Netherlands Lung Foundation, AstraZeneca, Boehringer Ingelheim, and Stichting Astma Bestrijding, all outside the submitted work. FMEF reports grants and personal fees from AstraZeneca, personal fees from Boehringer Ingelheim, personal fees from Chiesi, personal fees from GlaxoSmithKline, grants and personal fees from Novartis, and personal fees from TEVA, outside the submitted work. RP reports personal fees from MEDtalk and Health Investment. DJAJ has received lecture fees from Chiesi and Boehringer Ingelheim in the last 3 years, which are unrelated to this paper. All other authors declare that they have no conflicts of interest. No financial support was received for the preparation of this manuscript.
Members of online long COVID peer support groups with presumed COVID-19 (n=766): characteristics, received health care, and fatigue-related measures.DOCX File , 19 KB
Additional information regarding self-reported pre-existing comorbidities and symptoms during the acute phase of COVID-19 and at the moment of completing the surveys.DOCX File , 15 KB
The Checklist Individual Strength–subscale subjective fatigue.DOCX File , 24 KB
Self-constructed physical and mental fatigue based upon 3 items of the Checklist Individual Strength–subscale subjective fatigue.DOCX File , 15 KB
Flowchart of participants’ inclusion.DOCX File , 77 KB
Prevalence of normal, mild, and severe fatigue using the Checklist Individual Strength–subscale subjective fatigue at T1 and T2, the proportional flow, and the direction of change of fatigue stratified for type of diagnosis.DOCX File , 176 KB
- Docherty AB, Harrison EM, Green CA, Hardwick HE, Pius R, Norman L, ISARIC4C investigators. Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study. BMJ 2020 May 22;369:m1985 [FREE Full text] [CrossRef] [Medline]
- Carfì A, Bernabei R, Landi F. Persistent symptoms in patients after acute COVID-19. JAMA 2020 Aug 11;324(6):603. [CrossRef]
- Huang C, Huang L, Wang Y, Li X, Ren L, Gu X, et al. 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study. Lancet 2021 Jan 16;397(10270):220-232 [FREE Full text] [CrossRef] [Medline]
- Goërtz YMJ, Van Herck M, Delbressine JM, Vaes AW, Meys R, Machado FVC, et al. Persistent symptoms 3 months after a SARS-CoV-2 infection: the post-COVID-19 syndrome? ERJ Open Res 2020 Oct;6(4):00542-2020 [FREE Full text] [CrossRef] [Medline]
- Mahase E. Covid-19: What do we know about "long covid"? BMJ 2020 Jul 14;370:m2815. [CrossRef] [Medline]
- Nabavi N. Long covid: How to define it and how to manage it. BMJ 2020 Sep 07;370:m3489. [CrossRef] [Medline]
- Wong AW, Shah AS, Johnston JC, Carlsten C, Ryerson CJ. Patient-reported outcome measures after COVID-19: a prospective cohort study. Eur Respir J 2020 Nov;56(5):2003276 [FREE Full text] [CrossRef] [Medline]
- Meys R, Delbressine JM, Goërtz YMJ, Vaes AW, Machado FVC, Van Herck M, et al. Generic and respiratory-specific quality of life in non-hospitalized patients with COVID-19. J Clin Med 2020 Dec 09;9(12):3993 [FREE Full text] [CrossRef] [Medline]
- Vaes AW, Machado FVC, Meys R, Delbressine JM, Goertz YMJ, Van Herck M, et al. Care dependency in non-hospitalized patients with COVID-19. J Clin Med 2020 Sep 12;9(9):2946 [FREE Full text] [CrossRef] [Medline]
- Tenforde MW, Kim SS, Lindsell CJ, Billig Rose E, Shapiro NI, Files DC, CDC COVID-19 Response Team, et al. Symptom duration and risk factors for delayed return to usual health among outpatients with COVID-19 in a multistate health care systems network - United States, March-June 2020. MMWR Morb Mortal Wkly Rep 2020 Jul 31;69(30):993-998 [FREE Full text] [CrossRef] [Medline]
- Vaes AW, Goërtz YMJ, Van Herck M, Machado FVC, Meys R, Delbressine JM, et al. Recovery from COVID-19: a sprint or marathon? 6-month follow-up data from online long COVID-19 support group members. ERJ Open Res 2021 Apr 26;7(2):00141-2021 [FREE Full text] [CrossRef] [Medline]
- Belli S, Balbi B, Prince I, Cattaneo D, Masocco F, Zaccaria S, et al. Low physical functioning and impaired performance of activities of daily life in COVID-19 patients who survived hospitalisation. Eur Respir J 2020 Oct;56(4):2002096 [FREE Full text] [CrossRef] [Medline]
- Writing Committee for the COMEBAC Study Group, Morin L, Savale L, Pham T, Colle R, Figueiredo S, et al. Four-month clinical status of a cohort of patients after hospitalization for COVID-19. JAMA 2021 Apr 20;325(15):1525-1534. [CrossRef] [Medline]
- Townsend L, Dyer AH, Jones K, Dunne J, Mooney A, Gaffney F, et al. Persistent fatigue following SARS-CoV-2 infection is common and independent of severity of initial infection. PLoS One 2020;15(11):e0240784 [FREE Full text] [CrossRef] [Medline]
- Ream E, Richardson A. Fatigue: a concept analysis. Int J Nurs Stud 1996 Oct;33(5):519-529. [CrossRef] [Medline]
- Garrigues E, Janvier P, Kherabi Y, Le Bot A, Hamon A, Gouze H, et al. Post-discharge persistent symptoms and health-related quality of life after hospitalization for COVID-19. J Infect 2020 Dec;81(6):e4-e6 [FREE Full text] [CrossRef] [Medline]
- Lam MH, Wing Y, Yu MW, Leung C, Ma RCW, Kong APS, et al. Mental morbidities and chronic fatigue in severe acute respiratory syndrome survivors: long-term follow-up. Arch Intern Med 2009 Dec 14;169(22):2142-2147. [CrossRef] [Medline]
- Moldofsky H, Patcai J. Chronic widespread musculoskeletal pain, fatigue, depression and disordered sleep in chronic post-SARS syndrome; a case-controlled study. BMC Neurol 2011 Mar 24;11(1):37 [FREE Full text] [CrossRef] [Medline]
- Lee SH, Shin H, Park HY, Kim JL, Lee JJ, Lee H, et al. Depression as a mediator of chronic fatigue and post-traumatic stress symptoms in Middle East respiratory syndrome survivors. Psychiatry Investig 2019 Jan;16(1):59-64 [FREE Full text] [CrossRef] [Medline]
- Bronner MB, Haagsma JA, Dontje ML, Barmentloo L, Kouwenberg RMCEJ, Olde Loohuis AGM, et al. Long-term impact of a Q-fever outbreak: an evaluation of health symptoms, health-related quality of life, participation and health care satisfaction after ten years. J Psychosom Res 2020 Dec;139:110258 [FREE Full text] [CrossRef] [Medline]
- Karshikoff B, Sundelin T, Lasselin J. Role of inflammation in human fatigue: relevance of multidimensional assessments and potential neuronal mechanisms. Front Immunol 2017;8:21 [FREE Full text] [CrossRef] [Medline]
- Corona patiënten met langdurige klachten (Nederland). Facebook. URL: https://www.facebook.com/groups/236723204035929.9 [accessed 2020-06-04]
- Corona patiënten (met langdurige klachten) (Vlaanderen). Facebook. URL: https://www.facebook.com/groups/241043323639334/ [accessed 2020-06-04]
- Coronaplein. Website in Dutch. Long Fonds. URL: https://coronaplein.nu/ [accessed 2021-09-09]
- Greenhalgh T, Knight M, A'Court C, Buxton M, Husain L. Management of post-acute covid-19 in primary care. BMJ 2020 Aug 11;370:m3026. [CrossRef] [Medline]
- Machado FVC, Meys R, Delbressine JM, Vaes AW, Goërtz YMJ, van Herck M, et al. Construct validity of the Post-COVID-19 Functional Status Scale in adult subjects with COVID-19. Health Qual Life Outcomes 2021 Feb 03;19(1):40 [FREE Full text] [CrossRef] [Medline]
- Houben-Wilke S, Delbressine JM, Vaes AW, Goërtz YM, Meys R, Machado FV, et al. Understanding and being understood: information and care needs of 2113 patients with confirmed or suspected COVID-19. J Patient Exp 2021 Mar 08;8:2374373521997222 [FREE Full text] [CrossRef] [Medline]
- Vandenbroucke JP, von Elm E, Altman DG, Gøtzsche PC, Mulrow CD, Pocock SJ, STROBE Initiative. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration. Int J Surg 2014 Dec;12(12):1500-1524 [FREE Full text] [CrossRef] [Medline]
- ASolutions. Webpage in Dutch. URL: https://www.asolutions.nl/ [accessed 2021-09-09]
- International Standard Classification of Education ISCED 2011. UNESCO Institute for Statistics. URL: http://uis.unesco.org/sites/default/files/documents/international-standard-classification-of-education-isced-2011-en.pdf [accessed 2021-09-09]
- Vercoulen JH, Swanink CM, Fennis JF, Galama JM, van der Meer JW, Bleijenberg G. Dimensional assessment of chronic fatigue syndrome. J Psychosom Res 1994 Jul;38(5):383-392. [CrossRef] [Medline]
- Vercoulen J, Alberts M, Bleijenberg G. De Checklist Individual Strength (CIS). Gedragstherapie 1999;32:131-136. [CrossRef]
- Worm-Smeitink M, Gielissen M, Bloot L, van Laarhoven HWM, van Engelen BGM, van Riel P, et al. The assessment of fatigue: psychometric qualities and norms for the Checklist individual strength. J Psychosom Res 2017 Jul;98:40-46. [CrossRef] [Medline]
- Beurskens AJ, Bültmann U, Kant I, Vercoulen JH, Bleijenberg G, Swaen GM. Fatigue among working people: validity of a questionnaire measure. Occup Environ Med 2000 May;57(5):353-357 [FREE Full text] [CrossRef] [Medline]
- Panitz S, Kornhuber M, Hanisch F. The checklist individual strength (CIS20-R) in patients with amyotrophic lateral sclerosis - a longitudinal study. Acta Neurol Scand 2015 Jun;131(6):372-380. [CrossRef] [Medline]
- van Koulil S, Kraaimaat FW, van Lankveld W, van Riel PLCM, Evers AWM. A patient's perspective on multidisciplinary treatment gain for fibromyalgia: an indicator for pre-post treatment effects? Arthritis Rheum 2009 Dec 15;61(12):1626-1632 [FREE Full text] [CrossRef] [Medline]
- Evers AWM, Kraaimaat FW, van Riel PLCM, de Jong AJL. Tailored cognitive-behavioral therapy in early rheumatoid arthritis for patients at risk: a randomized controlled trial. Pain 2002 Nov;100(1-2):141-153. [CrossRef] [Medline]
- SankeyMATIC: a Sankey diagram builder for everyone. SankeyMATIC. URL: http://sankeymatic.com/ [accessed 2021-04-08]
- Daher A, Balfanz P, Cornelissen C, Müller A, Bergs I, Marx N, et al. Follow up of patients with severe coronavirus disease 2019 (COVID-19): Pulmonary and extrapulmonary disease sequelae. Respir Med 2020;174:106197 [FREE Full text] [CrossRef] [Medline]
- Stavem K, Ghanima W, Olsen MK, Gilboe HM, Einvik G. Prevalence and determinants of fatigue after COVID-19 in non-hospitalized subjects: a population-based study. Int J Environ Res Public Health 2021 Feb 19;18(4):2030 [FREE Full text] [CrossRef] [Medline]
- Goërtz YMJ, Spruit MA, Van 't Hul AJ, Peters JB, Van Herck M, Nakken N, et al. Fatigue is highly prevalent in patients with COPD and correlates poorly with the degree of airflow limitation. Ther Adv Respir Dis 2019;13:1753466619878128 [FREE Full text] [CrossRef] [Medline]
- Van Herck M, Spruit MA, Burtin C, Djamin R, Antons J, Goërtz YMJ, et al. Fatigue is highly prevalent in patients with asthma and contributes to the burden of disease. J Clin Med 2018 Nov 23;7(12):471 [FREE Full text] [CrossRef] [Medline]
- Van Heugten C, Köhler S, Francke M, Bol Y. The association between executive functioning, coping styles and depressive symptoms in patients with Multiple Sclerosis. Mult Scler Relat Disord 2019 Nov;36:101392. [CrossRef] [Medline]
- van Hoogmoed D, Fransen J, Bleijenberg G, van Riel P. Physical and psychosocial correlates of severe fatigue in rheumatoid arthritis. Rheumatology (Oxford) 2010 Jul;49(7):1294-1302. [CrossRef] [Medline]
- Kwakkenbos L, van Lankveld WGJM, Vonk MC, Becker ES, van den Hoogen FHJ, van den Ende CHM. Disease-related and psychosocial factors associated with depressive symptoms in patients with systemic sclerosis, including fear of progression and appearance self-esteem. J Psychosom Res 2012 Mar;72(3):199-204 [FREE Full text] [CrossRef] [Medline]
- Sigal LH. Summary of the first 100 patients seen at a Lyme disease referral center. Am J Med 1990 Jun;88(6):577-581. [CrossRef] [Medline]
- Straus SE, Tosato G, Armstrong G, Lawley T, Preble OT, Henle W, et al. Persisting illness and fatigue in adults with evidence of Epstein-Barr virus infection. Ann Intern Med 1985 Jan;102(1):7-16. [CrossRef] [Medline]
- Voss JG. Predictors and correlates of fatigue in HIV/AIDS. J Pain Symptom Manage 2005 Feb;29(2):173-184 [FREE Full text] [CrossRef] [Medline]
- Schanke AK, Stanghelle JK. Fatigue in polio survivors. Spinal Cord 2001 May;39(5):243-251. [CrossRef] [Medline]
- Epstein L, Wong KK, Kallen AJ, Uyeki TM. Post-Ebola signs and symptoms in U.S. survivors. N Engl J Med 2015 Dec 17;373(25):2484-2486. [CrossRef] [Medline]
- Korenromp IHE, Meeus M, Bleijenberg G. Dutch language area definition of chronic fatigue. Article in Dutch. Ned Tijdschr Geneeskd 2012;156(16):A4403. [Medline]
- Del Rio C, Collins LF, Malani P. Long-term health consequences of COVID-19. JAMA 2020 Nov 03;324(17):1723-1724. [CrossRef] [Medline]
- Garner P. The BMJ opinion: COVID-19 and fatigue – a game of snakes and ladders. BMJ Opinion. 2020. URL: https://blogs.bmj.com/bmj/2020/05/19/paul-garner-covid-19-and-fatigue-a-game-of-snakes-and-ladders/
- Humphreys H, Kilby L, Kudiersky N, Copeland R. Long COVID and the role of physical activity: a qualitative study. BMJ Open 2021 Mar 10;11(3):e047632 [FREE Full text] [CrossRef] [Medline]
- Janssen N, Kant IJ, Swaen GMH, Janssen PPM, Schröer CAP. Fatigue as a predictor of sickness absence: results from the Maastricht cohort study on fatigue at work. Occup Environ Med 2003 Jun;60(Suppl 1):i71-i76 [FREE Full text] [CrossRef] [Medline]
- McCrone P, Darbishire L, Ridsdale L, Seed P. The economic cost of chronic fatigue and chronic fatigue syndrome in UK primary care. Psychol Med 2003 Feb;33(2):253-261. [CrossRef] [Medline]
- Sabes-Figuera R, McCrone P, Hurley M, King M, Donaldson AN, Ridsdale L. The hidden cost of chronic fatigue to patients and their families. BMC Health Serv Res 2010 Mar 04;10:56 [FREE Full text] [CrossRef] [Medline]
- Menting J, Tack CJ, Bleijenberg G, Donders R, Droogleever Fortuyn HA, Fransen J, et al. Is fatigue a disease-specific or generic symptom in chronic medical conditions? Health Psychol 2018 Jun;37(6):530-543. [CrossRef] [Medline]
- Spruit MA, Vercoulen JH, Sprangers MAG, Wouters EFM, FAntasTIGUE consortium. Fatigue in COPD: an important yet ignored symptom. Lancet Respir Med 2017 Jul;5(7):542-544. [CrossRef] [Medline]
- Ferraro F, Calafiore D, Dambruoso F, Guidarini S, de Sire A. COVID-19 related fatigue: which role for rehabilitation in post-COVID-19 patients? A case series. J Med Virol 2021 Apr;93(4):1896-1899. [CrossRef] [Medline]
- Vink M, Vink-Niese A. Could cognitive behavioural therapy be an effective treatment for long COVID and post COVID-19 fatigue syndrome? Lessons from the Qure Study for Q-Fever Fatigue Syndrome. Healthcare (Basel) 2020 Dec 11;8(4):552 [FREE Full text] [CrossRef] [Medline]
- Van Herck M, Antons J, Vercoulen JH, Goërtz YMJ, Ebadi Z, Burtin C, et al. Pulmonary rehabilitation reduces subjective fatigue in COPD: a responder analysis. J Clin Med 2019 Aug 20;8(8):1264 [FREE Full text] [CrossRef] [Medline]
- Rimes KA, Chalder T. Treatments for chronic fatigue syndrome. Occup Med (Lond) 2005 Jan;55(1):32-39. [CrossRef] [Medline]
- Gloeckl R, Leitl D, Jarosch I, Schneeberger T, Nell C, Stenzel N, et al. Benefits of pulmonary rehabilitation in COVID-19: a prospective observational cohort study. ERJ Open Res 2021 Apr 11;7(2):00108-2021 [FREE Full text] [CrossRef] [Medline]
- Daynes E, Gerlis C, Chaplin E, Gardiner N, Singh SJ. Early experiences of rehabilitation for individuals post-COVID to improve fatigue, breathlessness exercise capacity and cognition - A cohort study. Chron Respir Dis 2021;18:14799731211015691 [FREE Full text] [CrossRef] [Medline]
- Davis HE, Assaf GS, McCorkell L, Wei H, Low RJ, Re'em Y, et al. Characterizing long COVID in an international cohort: 7 months of symptoms and their impact. EClinicalMedicine 2021 Aug;38:101019 [FREE Full text] [CrossRef] [Medline]
- Ladds E, Rushforth A, Wieringa S, Taylor S, Rayner C, Husain L, et al. Persistent symptoms after Covid-19: qualitative study of 114 "long Covid" patients and draft quality principles for services. BMC Health Serv Res 2020 Dec 20;20(1):1144 [FREE Full text] [CrossRef] [Medline]
- Maes IHL, Delespaul PAEG, Peters ML, White MP, van Horn Y, Schruers K, et al. Measuring health-related quality of life by experiences: the experience sampling method. Value Health 2015 Jan;18(1):44-51 [FREE Full text] [CrossRef] [Medline]
- COVID-19 rapid guideline: managing the long-term effects of COVID-19. National Institute for Health and Care Excellence. URL: https://www.nice.org.uk/guidance/ng188 [accessed 2021-01-21]
- Sudre CH, Murray B, Varsavsky T, Graham MS, Penfold RS, Bowyer RC, et al. Attributes and predictors of long COVID. Nat Med 2021 Apr;27(4):626-631. [CrossRef] [Medline]
- Chalder T, Berelowitz G, Pawlikowska T, Watts L, Wessely S, Wright D, et al. Development of a fatigue scale. J Psychosom Res 1993;37(2):147-153. [CrossRef] [Medline]
- Hertting O. More research is needed on the long-term effects of COVID-19 on children and adolescents. Acta Paediatr 2021 Mar;110(3):744-745 [FREE Full text] [CrossRef] [Medline]
- Magnusson K, Skyrud K, Suren P, Greve-Isdahl M, Størdal K, Kristoffersen D. Health care use up to 6 months after COVID-19 in 700.000 children and adolescents: a pre-post study. medRxiv Preprint posted online on June 05, 2021. [CrossRef]
|CIS-Fatigue: Checklist Individual Strength–subscale subjective fatigue|
|CT: computed tomography|
|GP: general practitioner|
|ICU: intensive care unit|
|MERS: Middle East respiratory syndrome|
|OT: occupational therapist|
|PCR: polymerase chain reaction|
|QoL: quality of life|
|SARS: severe acute respiratory syndrome|
|STROBE: Strengthening the Reporting of Observational Studies in Epidemiology|
|T1: time point of completing the first survey|
|T2: time point of completing the second survey|
Edited by C Basch; submitted 08.05.21; peer-reviewed by B Chaudhry, C Roldan; comments to author 28.06.21; revised version received 31.07.21; accepted 29.08.21; published 21.09.21Copyright
©Maarten Van Herck, Yvonne M J Goërtz, Sarah Houben-Wilke, Felipe V C Machado, Roy Meys, Jeannet M Delbressine, Anouk W Vaes, Chris Burtin, Rein Posthuma, Frits M E Franssen, Bita Hajian, Herman Vijlbrief, Yvonne Spies, Alex J van 't Hul, Daisy J A Janssen, Martijn A Spruit. Originally published in the Journal of Medical Internet Research (https://www.jmir.org), 21.09.2021.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work, first published in the Journal of Medical Internet Research, is properly cited. The complete bibliographic information, a link to the original publication on https://www.jmir.org/, as well as this copyright and license information must be included.